Clinical Trial Update: Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing long-term antibody persistence of MenACWY-TT (GSK134612) with Mencevax ACWY in healthy adolescents and adults, plus booster response a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• MenACWY-TT (Meningococcal ACWY tetanus toxoid conjugate vaccine)
• Mencevax ACWY

Snippet

Sponsor: Pfizer | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-08-28